

Press Release
Västra Frölunda, Sweden, May 5, 2009

ARTIMPLANT INTERIM REPORT JANUARY – MARCH 2009

- **Net revenue for the first quarter amounted to SEK 4.8 million (2.1)***
- **The net loss for the first quarter totaled SEK 4.5 million (6.2)**
- **Earnings per share for the first quarter amounted to SEK -0.08 (-0.10)**
- **Sales of Artelon[®] Spacer totaled SEK 3.5 million (1.3)**
- **Sales of Artelon[®] Tissue Reinforcement amounted to SEK 1.3 million (0.8)**
- **Spacer agreements with Small Bone Innovations have been made non-exclusive and Artimplant's margin per unit sold has increased significantly**

Event after the period-end

- **The Schulthess Clinic in Zurich has been granted clearance by Swissmedic to commence a clinical investigation of treatment of lumbar facet joints using an Artelon[®] implant.**
- **The agreement with Biomet Sports Medicine has been revised, giving Artimplant a better margin in return for responsibility for clinical market studies.**

N.B. This is a translation from Swedish. The Swedish version shall always take precedence.

Artimplant will present this report at the Annual Meeting on May 5, 2009, at 5pm, Central European Time (GMT+1). The presentation will be published on the Company's website after the meeting. No telephone conference will be held by reason of this report. For further information and full interim report see www.artimplant.com.

* Figures in brackets refer to the corresponding period last year

For additional information, please contact:

Hans Rosén, CEO, phone +46 (0)31-746 56 00, +46 (0)708 58 34 70, hans.rosen@artimplant.com

Lars-Johan Cederbrant, CFO, phone +46 (0)31-746 56 54, +46 (0)703 01 68 54,
lars-johan.cederbrant@artimplant.com

Further information at www.artimplant.com where one also can subscribe to future press releases;
www.artimplant.com/investors-media/subscribe-to-press-releases.html

Artimplant

Artimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery. We restore health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon[®], meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder and other soft tissue injuries as well as oral surgery and veterinary medical applications.



Artimplant AB
Hulda Mellgrens gata 5
SE-421 32 Västra Frölunda
SWEDEN

Phone +46 (0)31 746 56 00
Fax +46 (0)31 746 56 60
Web www.artimplant.com
Reg. No. 556404-8394

Artimplant is a public company listed on the NASDAQ OMX Stockholm Exchange in the Small Cap segment and in the healthcare sector.

Forward-looking statements

This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

This is information which Artimplant is required to make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. This information was made available for publication on May 5, 2009 at 3 PM (GMT+1).